Navigation Links
Beckman Coulter Announces Licensing Agreements for Molecular Tests with National University of Ireland, Galway
Date:1/22/2008

Contracts Give Access to Diagnostic Application of Research Technologies

FULLERTON, Calif., Jan. 22 /PRNewswire-FirstCall/ -- Beckman Coulter, Inc. (NYSE: BEC) announced today that it has signed four agreements with National University of Ireland, Galway (NUI Galway) to direct assay research and acquire licenses for intellectual property that will enable development of infectious disease tests for the company's future molecular diagnostic instrument. Under the terms of the three-to-five year agreements, research will begin in early 2008.

(Logo: http://www.newscom.com/cgi-bin/prnh/20031202/BECLOGO)

"With these agreements, we will take a big step toward the launch of our 'sample-to-result' molecular diagnostic system, including a differentiated menu of moderately complex tests that address urgent clinical decisions," commented Mike Whelan, group vice president of Beckman Coulter's High Sensitivity Testing Group. "The agreements give us access to intellectual property for the development of tests for infectious diseases including sepsis; hospital-acquired infections; and sexually transmitted diseases, such as Chlamydia and Neisseria." Infectious disease testing comprises about 50 percent of the $2 billion molecular diagnostics market in the United States.

The assay development research relies on NUI Galway nucleic acid detection technology for both bacterial and fungal targets along with SPRI(R) (Solid Phase Reversible Immobilization) and other technologies from Beckman Coulter.

Whelan added, "The combination of NUI Galway technologies with ours gives us a glimpse of the next generation of molecular diagnostics. Our goal is that our simplified, automated solution will allow these time-consuming, complex, and labor-intensive tests to migrate into the routine hospital lab. So physicians will get diagnostic information within hours, instead of days or weeks, and be able to begin treating patients much sooner."

Welcoming this new partnership with Beckman Coulter, Dr. Iognaid O Muircheartaigh, NUI Galway president, praised the work of the researchers leading this initiative. "These leading-edge researchers are addressing some of the most challenging and important issues at the frontier of modern biomedical research -- with the ultimate goal of changing the way patients are diagnosed. The research and technology development collaboration with Beckman Coulter is a strong endorsement from industry of the quality and importance of the research being undertaken at NUI Galway."

"We are excited to partner with Beckman Coulter on this unique initiative," said Dr. Daniel O'Mahony, director, Technology Transfer at NUI Galway. "It underpins our commitment to, and support of, research excellence and exemplifies our stated research strategy: creating an environment that values intellectual property, and promoting technology transfer and commercialization activity among University researchers and industry partners. This collaboration brings together molecular diagnostic expertise at NUI Galway with automated solution expertise at Beckman Coulter that will result in the development of break-through technologies for the diagnosis of a variety of infectious diseases in humans."

Established in 1845 as Queen's College Galway, National University of Ireland, Galway is one of Ireland's foremost centers of academic excellence. With more than 15,000 students, it has a long-established reputation of teaching and research excellence in each of its six colleges -- Arts, Social Sciences and Celtic Studies; Science; Law; Commerce; Engineering and Informatics; Medicine, Nursing and Health Sciences.

Beckman Coulter, Inc., based in Fullerton, California, develops, manufactures and markets products that simplify, automate and innovate complex biomedical tests. More than 200,000 Beckman Coulter systems operate in laboratories around the world supplying critical information for improving patient health and reducing the cost of care. Recurring revenue, consisting of supplies, test kits, service and operating-type lease payments, represents more than 75 percent of the company's 2006 annual revenue of $2.53 billion.
For more information, visit http://www.beckmancoulter.com.

Contacts: Mary Luthy

Corporate Communications, Beckman Coulter

Phone: (714) 993-8770

E-mail: mluthy@beckman.com

Allan Harris

Investor Relations, Beckman Coulter

Phone: (714) 773-7620

E-mail: adharris@beckman.com


'/>"/>
SOURCE Beckman Coulter, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine technology :

1. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
2. EDAP Announces Launch of Clinical Study Combining HIFU and Chemotherapy for Localized Aggressive High Risk Prostate Cancer
3. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
4. ADVENTRX Announces Fast Track Designation Granted By the FDA For CoFactor For the Treatment of Metastatic Colorectal Cancer
5. DOV Pharmaceutical, Inc. Announces Successful Phase Ib Results for DOV 21,947
6. Phosphagenics Announces Positive Phase 1b Transdermal Insulin Clinical Trial Results
7. Xenomics Announces Implementation of its First Diagnostic Test for Acute Myeloid Leukemia Into Clinical Practice
8. Emisphere Technologies, Inc. Announces 2007 Second Quarter Financial Results
9. Amicus Therapeutics Announces Second Quarter 2007 Financial Results
10. Genta Incorporated Announces Second Quarter 2007 Financial Results and Corporate Highlights
11. MicroDose Announces Positive Results From the QDose Inhaled Insulin Glucose Clamp Study
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/8/2017)... May 8, 2017  Diplomat Pharmacy, Inc. (NYSE: DPLO)., ... ("WRB"), a health care service center company based ... WRB specializes in relationship management programs for leading pharmaceutical ... WRB will join Envoy Health ... services for manufacturers, biotech firms, and other service companies. ...
(Date:5/4/2017)... Tenn. , May 4, 2017  A ... Infection Control, Ultraviolet-C light as a ... Tru-D SmartUVC,s ability to reduce bioburden on anesthesia ... bioburden reduction on high-touch, complex medical equipment surfaces ... surgical infections. "This study further validates ...
(Date:5/4/2017)...   BioLife Solutions , Inc. (NASDAQ: ... proprietary clinical grade hypothermic storage and ... announced that the Company,s first quarter 2017 financial results ... 11, 2017, and that the Company will host a ... that afternoon. Management will provide an overview of the ...
Breaking Medicine Technology:
(Date:5/27/2017)... Los Angeles, California (PRWEB) , ... May 26, 2017 , ... ... Canadian senior citizens who visit a doctor for colds or respiratory issues that are ... note that excessive time pressure on doctors may be largely responsible for the problem ...
(Date:5/27/2017)... Rosa, CA (PRWEB) , ... May 27, 2017 , ... ... cause for concern, but a new study from the Osteoarthritis Initiative shows ... to developing knee osteoarthritis. Knowing this in advance may give doctors the opportunity to ...
(Date:5/26/2017)... Fairfax, VA (PRWEB) , ... May 26, 2017 ... ... is pleased to announce a new educational seminar to focus on current legislative ... Regulatory News(LEARN) seminar will begin at 1 p.m. Sunday, Sept. 10, and will ...
(Date:5/26/2017)... ... 26, 2017 , ... Boar’s Head Brand®, one of the ... Day entertaining that are sure to satisfy your guests’ flavor cravings, while adding ... cheeses featured in these refreshingly balanced recipes are packed with flavor, creating the ...
(Date:5/26/2017)... ... May 26, 2017 , ... Yisrayl Hawkins, Pastor and Overseer at The House ... focusing on the Peace Agreements being discussed by President Donald Trump and the rest ... to try to speed up peace talks in the continuous battle between Israel and ...
Breaking Medicine News(10 mins):